Skip to content
Annalist
Companies Compare Method Data Quality For AI agents

Eli Lilly and Company

LLY · NYSE · Health care, pharmaceuticals · United States · US GAAP · Fiscal year ends December

Latest report: Q2 FY2026, the quarter ended 30 June 2026, released 5 August 2026. Snapshot FY2026Q2_ddc45f69.

Overview

Revenue, quarter
+47.7% year on year
Pre-tax income, quarter
+36.4% year on year
Net income, quarter
+25.3% year on year
Diluted EPS, quarter
+26.2% year on year
Pre-tax margin, last 4 quarters
+10.5pp year on year
Return on equity, last 4 quarters
+15.7pp year on year

Select a figure to see the document it came from.

Key Findings

Findings for the latest quarter, with their history over earlier quarters.

  1. Revenue for the quarter ended 30 June 2026 was US$23.0 billion, 47.7% higher than in the same quarter a year earlier.

    Weakenedin Q2 FY2026 · stated since Q2 FY2024
    Rule: Revenue against a year earlier · Sources 10-Q 2026-06
    History of this finding, 9 records
    1. Q2 FY2026 WeakenedRevenue for the quarter ended 30 June 2026 was US$23.0 billion, 47.7% higher than in the same quarter a year earlier.Recorded from FY2026Q2_08553944 · data update
    2. Q1 FY2026 StrengthenedRevenue for the quarter ended 31 March 2026 was US$19.8 billion, 55.5% higher than in the same quarter a year earlier.Reconstructed · data update
    3. Q4 FY2025 WeakenedRevenue for the quarter ended 31 December 2025 was US$19.3 billion, 42.6% higher than in the same quarter a year earlier.Reconstructed · data update
    4. Q3 FY2025 StrengthenedRevenue for the quarter ended 30 September 2025 was US$17.6 billion, 53.9% higher than in the same quarter a year earlier.Reconstructed · data update
    5. Q2 FY2025 WeakenedRevenue for the quarter ended 30 June 2025 was US$15.6 billion, 37.6% higher than in the same quarter a year earlier.Reconstructed · data update
    6. Q1 FY2025 ConfirmedRevenue for the quarter ended 31 March 2025 was US$12.7 billion, 45.2% higher than in the same quarter a year earlier.Reconstructed · data update
    7. Q4 FY2024 StrengthenedRevenue for the quarter ended 31 December 2024 was US$13.5 billion, 44.7% higher than in the same quarter a year earlier.Reconstructed · data update
    8. Q3 FY2024 WeakenedRevenue for the quarter ended 30 September 2024 was US$11.4 billion, 20.4% higher than in the same quarter a year earlier.Reconstructed · data update
    9. Q2 FY2024 NewRevenue for the quarter ended 30 June 2024 was US$11.3 billion, 36.0% higher than in the same quarter a year earlier.Reconstructed · initial
  2. Net income attributable to the company was US$7.1 billion, 25.3% higher than in the same quarter a year earlier.

    Weakenedin Q2 FY2026 · stated since Q4 FY2024
    Rule: Net income against a year earlier · Sources 10-Q 2026-06
    History of this finding, 11 records
    1. Q2 FY2026 WeakenedNet income attributable to the company was US$7.1 billion, 25.3% higher than in the same quarter a year earlier.Recorded from FY2026Q2_08553944 · data update
    2. Q1 FY2026 StrengthenedNet income attributable to the company was US$7.4 billion, 168.1% higher than in the same quarter a year earlier.Reconstructed · data update
    3. Q4 FY2025 WeakenedNet income attributable to the company was US$6.6 billion, 50.5% higher than in the same quarter a year earlier.Reconstructed · data update
    4. Q3 FY2025 StrengthenedNet income attributable to the company was US$5.6 billion, 475.3% higher than in the same quarter a year earlier.Reconstructed · data update
    5. Q2 FY2025 StrengthenedNet income attributable to the company was US$5.7 billion, 90.8% higher than in the same quarter a year earlier.Reconstructed · data update
    6. Q1 FY2025 WeakenedNet income attributable to the company was US$2.8 billion, 23.0% higher than in the same quarter a year earlier.Reconstructed · data update
    7. Q4 FY2024 NewNet income attributable to the company was US$4.4 billion, 101.4% higher than in the same quarter a year earlier.Reconstructed · data update
    8. Q4 FY2024 RetiredThe finding changed to higher than a year earlier.Reconstructed · data update
    9. Q3 FY2024 NewNet income attributable to the company was US$970 million, against a net loss of US$57 million in the same quarter a year earlier.Reconstructed · data update
    10. Q3 FY2024 RetiredThe finding changed to a profit after a loss a year earlier.Reconstructed · data update
    11. Q2 FY2024 NewNet income attributable to the company was US$3.0 billion, 68.3% higher than in the same quarter a year earlier.Reconstructed · initial
  3. Return on equity over the last 4 quarters was 102.4%, against 86.7% a year earlier.

    Weakenedin Q2 FY2026 · stated since Q3 FY2024
    Rule: Return on equity against a year earlier · Sources 10-Q 2025-06, 10-Q 2026-06, 10-Q 2025-09 and 3 more
    History of this finding, 10 records
    1. Q2 FY2026 WeakenedReturn on equity over the last 4 quarters was 102.4%, against 86.7% a year earlier.Recorded from FY2026Q2_08553944 · data update
    2. Q1 FY2026 StrengthenedReturn on equity over the last 4 quarters was 107.6%, against 77.7% a year earlier.Reconstructed · data update
    3. Q4 FY2025 WeakenedReturn on equity over the last 4 quarters was 101.2%, against 84.6% a year earlier.Reconstructed · data update
    4. Q3 FY2025 StrengthenedReturn on equity over the last 4 quarters was 96.8%, against 65.7% a year earlier.Reconstructed · data update
    5. Q2 FY2025 ConfirmedReturn on equity over the last 4 quarters was 86.7%, against 59.6% a year earlier.Reconstructed · data update
    6. Q1 FY2025 WeakenedReturn on equity over the last 4 quarters was 77.7%, against 51.1% a year earlier.Reconstructed · data update
    7. Q4 FY2024 StrengthenedReturn on equity over the last 4 quarters was 84.6%, against 48.9% a year earlier.Reconstructed · data update
    8. Q3 FY2024 NewReturn on equity over the last 4 quarters was 65.7%, against 46.9% a year earlier.Reconstructed · data update
    9. Q3 FY2024 RetiredThe finding changed to higher than a year earlier.Reconstructed · data update
    10. Q2 FY2024 NewReturn on equity over the last 4 quarters was 59.6%, against 66.3% a year earlier.Reconstructed · initial
  4. Net debt was US$46.0 billion at 30 June 2026.

    Strengthenedin Q2 FY2026 · stated since Q2 FY2024
    Rule: Net debt or net cash · Sources 10-Q 2026-06
    History of this finding, 9 records
    1. Q2 FY2026 StrengthenedNet debt was US$46.0 billion at 30 June 2026.Recorded from FY2026Q2_08553944 · data update
    2. Q1 FY2026 StrengthenedNet debt was US$38.1 billion at 31 March 2026.Reconstructed · data update
    3. Q4 FY2025 StrengthenedNet debt was US$35.2 billion at 31 December 2025.Reconstructed · data update
    4. Q3 FY2025 WeakenedNet debt was US$32.6 billion at 30 September 2025.Reconstructed · data update
    5. Q2 FY2025 ConfirmedNet debt was US$36.4 billion at 30 June 2025.Reconstructed · data update
    6. Q1 FY2025 ConfirmedNet debt was US$35.3 billion at 31 March 2025.Reconstructed · data update
    7. Q4 FY2024 StrengthenedNet debt was US$34.6 billion at 31 December 2024.Reconstructed · data update
    8. Q3 FY2024 StrengthenedNet debt was US$27.6 billion at 30 September 2024.Reconstructed · data update
    9. Q2 FY2024 NewNet debt was US$25.5 billion at 30 June 2024.Reconstructed · initial

Records before Q2 FY2026 are reconstructed from the latest snapshot. Ledger: findings.json. Correction of 19 October 2026: Annalist counted the commercial paper of Eli Lilly twice. It was captured as short-term borrowings and is also part of the current debt that the company reports, so total debt was overstated by US$1.50 billion at 31 December 2022, US$6.19 billion at 31 December 2023 and US$4.34 billion at 31 December 2024. Records 5, 21 and 23 cite figures that the correction changed. Record 64 states the corrected finding: lease-adjusted debt of 2.2 times adjusted EBITDA for fiscal 2024, in the intermediate band. Correction of 20 October 2026: The quarters of Eli Lilly now come from one set of filings each: operating cash flow, investing cash flow and research and development of several quarters of 2020 and 2021 had mixed figures of different filings. Dividends per share of 11 quarters derived from the figures of 2 filings are no longer published. Records 69 and 70 state the corrected findings. Records 3, 5, 6, 7, 14, 16, 17, 19, 20, 31, 36, 41, 43, 48, 57, 63, 66 and 68 cite figures that the correction changed. Correction of 22 October 2026: Changes against a year earlier compared 2 figures of different bases where a stock split, a spin-off or a restatement came between the 2 periods. 7 growth values of Eli Lilly changed, each by less than 0.1 percentage points. Record 17 cites figures of 2 bases, which give the same rounded change as one basis.

Credit, liquidity, earnings quality and score findings: Analysis.

Data

Source documents26 documents, latest Form 10-Q, period ended 30 June 2026List
DownloadsExcel workbook · JSON
SnapshotFY2026Q2_ddc45f69

Corporate Events

No corporate event found in the filings since 2020.

Earnings, Returns and Balance Sheet

Revenue

By quarter, US dollars

Income Before Income Taxes

By quarter, US dollars

Net Income Attributable to the Company

By quarter, US dollars

Margins

Last 4 quarters at each quarter end, per cent

Returns

Last 4 quarters, per cent

Free Cash Flow

Operating cash flow less capital expenditure, by quarter, US dollars

Net Debt

Total debt less cash and short-term investments, at quarter end, US dollars

Diluted Earnings per Share

By quarter, as reported

Financial Statements

Figures as filed. Select a figure for its source document and method; a small d marks a quarter derived from cumulative reports.

The statements are loading. They are also available as JSON and CSV.

Ratios

Select a ratio for its formula and the figures it uses, each with its document; (i) gives its definition.

The ratios are loading.

Source Documents

Documents of this snapshot, latest first.

DocumentDateId
Form 10-Q, period ended 30 June 20265 Aug 202610-Q:0000059478-26-000081
Form 10-Q, period ended 31 March 202630 Apr 202610-Q:0000059478-26-000045
Form 10-K, period ended 31 December 202512 Feb 202610-K:0000059478-26-000013
Form 10-Q, period ended 30 September 202530 Oct 202510-Q:0000059478-25-000254
Form 10-Q, period ended 30 June 20257 Aug 202510-Q:0000059478-25-000204
Form 10-Q, period ended 31 March 20251 May 202510-Q:0000059478-25-000132
Form 10-K, period ended 31 December 202419 Feb 202510-K:0000059478-25-000067
Form 10-Q, period ended 30 September 202430 Oct 202410-Q:0000059478-24-000245
Form 10-Q, period ended 30 June 20248 Aug 202410-Q:0000059478-24-000187
Form 10-Q, period ended 31 March 202430 Apr 202410-Q:0000059478-24-000118
Form 10-K, period ended 31 December 202321 Feb 202410-K:0000059478-24-000065
Form 10-Q, period ended 30 September 20232 Nov 202310-Q:0000059478-23-000284
Form 10-Q, period ended 30 June 20238 Aug 202310-Q:0000059478-23-000221
Form 10-Q, period ended 31 March 202327 Apr 202310-Q:0000059478-23-000162
Form 10-K, period ended 31 December 202222 Feb 202310-K:0000059478-23-000082
Form 10-Q, period ended 30 September 20221 Nov 202210-Q:0000059478-22-000250
Form 10-Q, period ended 30 June 20224 Aug 202210-Q:0000059478-22-000196
Form 10-Q, period ended 31 March 202229 Apr 202210-Q:0000059478-22-000133
Form 10-K, period ended 31 December 202123 Feb 202210-K:0000059478-22-000068
Form 10-Q, period ended 30 September 202127 Oct 202110-Q:0000059478-21-000216
Form 10-Q, period ended 30 June 20213 Aug 202110-Q:0000059478-21-000171
Form 10-Q, period ended 31 March 202130 Apr 202110-Q:0000059478-21-000122
Form 10-K, period ended 31 December 202017 Feb 202110-K:0000059478-21-000083
Form 10-Q, period ended 30 September 202028 Oct 202010-Q:0000059478-20-000155
Form 10-Q, period ended 30 June 202031 Jul 202010-Q:0000059478-20-000131
Form 10-Q, period ended 31 March 20201 May 202010-Q:0000059478-20-000104

Checks

216191 of 216 checks passed, 25 warnings
Fiscal calendar68 passedFiscal years last 350 to 380 days, quarters 80 to 125 days, and each period starts on the day after the one before. Checked at error level.
Quarters and fiscal year75 of 93 passedThe 4 quarters of every item add up to its fiscal year, or a later filing restated the year. Checked at error level; a difference that a later report explains is a warning, which does not stop publication.
Research and development expense, FY2020: $6,086m against $5,976m
Revenue, FY2023: $34,124m against $34,124m
Cost of revenue, FY2023: $7,082m against $7,082m
Research and development expense, FY2023: $9,313m against $9,313m
Selling, general and administrative expense, FY2023: $7,403m against $7,404m
Interest expense, FY2023: $486m against $486m
Withheld values2 values withheldA value that contradicts the definition of its item, or that documents report in contradiction, is withheld. Checked at warning level.
Proceeds from issuance of long-term debt, Q4 FY2024: withheld, negative where the item cannot be negative
Proceeds from issuance of long-term debt, Q4 FY2025: withheld, negative where the item cannot be negative
Filer identity1 passedThe documents are those of the company of this page. Checked at error level.
Balance sheet identity26 passedTotal assets equal total liabilities and equity at each balance sheet date. Checked at error level.
Lease liabilities5 passedLease payments due, less imputed interest, equal the lease liabilities. Checked at warning level.
Debt maturities0 of 5 passedThe debt maturity schedule adds up to the long-term debt. Checked at warning level.
31 Dec 2020: $3,070m against $16,595m
31 Dec 2021: $3,819m against $16,885m
31 Dec 2022: $2,996m against $14,741m
31 Dec 2023: $4,318m against $19,036m
31 Dec 2024: $8,344m against $29,306m
Quarters and 9 months10 passedThe 3 reported quarters of a fiscal year add up to the reported 9-month figure. Checked at error level.
Earnings per share6 passedNet income divided by average shares agrees with reported basic earnings per share. Checked at warning level.

Data Quality

How many values of this snapshot the checks prove, and how many Annalist derives, withholds and tracks as restated. Every company.

Values published1,266
Proven by a check34.2%, 433 values
Confirmed by a second document0.0%, 0 values
Derived from reported figures16.3%, 206 values
Values withheld2
Restated figures tracked105
Changes compared on one basis11
Company lines mapped0 of 0 reviewed

Citation

Annalist, Eli Lilly and Company, snapshot eli-lilly/FY2026Q2_ddc45f69 (as of FY2026 Q2); <item label>, <period>; source <document id> (<document url>)

Snapshot FY2026Q2_ddc45f69 · dataset SHA-256 ddc45f69408cf5f8b257be6173ee046792c9683c4b859d4dc2894e86069c76a4 · findings rules 0.4

Data: info.json · dataset.json · validation.json · documents.json